Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bupivacaine Infiltration for Pain After Cesarean Section
NCT05404490Completed
- Sponsor
- Hospital Santo Tomás
- Start
- Jun 2022
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, single-blind trial in postoperative pain comparing Bupivacaine with Placebo (2 arms). Primary endpoint: Post operative pain (Visual Analogue Scale) at 72 hours. Started Jun 2022; status: completed.
02
Drugs
bupivacaine hydrochloride 0.75% injection
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT05404490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05404490.